2.34
Palisade Bio Inc stock is traded at $2.34, with a volume of 4.93M.
It is up +7.83% in the last 24 hours and up +25.81% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.17
Open:
$2.23
24h Volume:
4.93M
Relative Volume:
0.68
Market Cap:
$21.34M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1673
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
+25.13%
1M Performance:
+25.81%
6M Performance:
+217.55%
1Y Performance:
-4.10%
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PALI
Palisade Bio Inc
|
2.34 | 323.77M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palisade Bio Inc Stock (PALI) Latest News
Using RSI to spot recovery in Palisade Bio Inc.2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Will Palisade Bio Inc. stock deliver consistent dividendsMarket Rally & Weekly High Return Opportunities - newser.com
How Palisade Bio Inc. stock performs after earnings2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
Can Palisade Bio Inc. stock attract ESG capital inflowsJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Will Palisade Bio Inc. (7NS0) stock deliver compounding returnsM&A Rumor & Real-Time Sentiment Analysis - newser.com
How big funds are accumulating Palisade Bio Inc. (7NS0) stockInsider Buying & Comprehensive Market Scan Insights - newser.com
Using data filters to optimize entry into Palisade Bio Inc.2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Why Palisade Bio Inc. (7NS0) stock is upgraded to buy - newser.com
Why Palisade Bio Inc. stock could be next big winnerRisk Management & Fast Moving Market Watchlists - newser.com
What MACD and RSI say about Palisade Bio Inc.2025 Market Sentiment & Daily Profit Focused Screening - newser.com
Why Palisade Bio Inc. stock remains resilientEarnings Overview Report & Low Drawdown Trading Techniques - newser.com
Will Palisade Bio Inc. stock deliver better than expected guidanceJuly 2025 Summary & Technical Pattern Based Buy Signals - newser.com
Palisade Bio Inc. stock momentum explainedGold Moves & Daily Profit Focused Stock Screening - newser.com
Palisade Bio (PALI) Price Target Increased by 45.83% to 11.90 - Nasdaq
Is Bharat Dynamics Limited Stock Set to Outperform Its Peers in YEAR - earlytimes.in
Palisade Bio Surges: Maxim Raises Price Target Amid Financing Boost - StocksToTrade
Forecasting Palisade Bio Inc. price range with options dataJuly 2025 Decliners & Verified Short-Term Plans - newser.com
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Should I hold or sell Palisade Bio Inc. stock in 2025July 2025 Breakouts & AI Optimized Trade Strategies - newser.com
Is Palisade Bio Inc. stock cheap at current valuationWeekly Trade Report & Capital Protection Trading Alerts - Fundação Cultural do Pará
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):